Gainers

• Werewolf Therapeutics (NASDAQ:HOWL) shares increased by 108.1% to $0.9 during Friday's regular session. The market value of their outstanding shares is at $20.9 million.
• Jupiter Neurosciences (NASDAQ:JUNS) stock rose 24.75% to $6.45. The company's market cap stands at $3.9 million.
• Arcturus Therapeutics (NASDAQ:ARCT) shares moved upwards by 21.2% to $13.32. The market value of their outstanding shares is at $312.3 million.
• Strive (NASDAQ:ASST) stock rose 17.17% to $18.9. The company's market cap stands at $1.3 billion.
• Eloxx Pharma (NASDAQ:ELOX) shares rose 16.74% to $21.06. The company's market cap stands at $61.9 million.
• Lisata Therapeutics (NASDAQ:LSTA) stock increased by 16.4% to $1.3. The company's market cap stands at $10.0 million.

Losers

• iSpecimen (NASDAQ:ISPC) stock declined by 22.9% to $1.75 during Friday's regular session. The market value of their outstanding shares is at $5.7 million.
• Profusa (NASDAQ:PFSA) stock decreased by 17.44% to $6.25. The company's market cap stands at $4.0 million. The company's, Q2 earnings came out yesterday.
• ZeroStack (NASDAQ:ZSTK) stock fell 12.57% to $5.15. The market value of their outstanding shares is at $14.2 million.
• NexGel (NASDAQ:NXGL) stock decreased by 12.06% to $0.34. The market value of their outstanding shares is at $3.7 million. The company's, Q2 earnings came out 4 days ago.
• EUDA Health Holdings (NASDAQ:EUDA) stock fell 10.36% to $12.73. The market value of their outstanding shares is at $42.5 million.
• Exicure (NASDAQ:XCUR) shares decreased by 9.62% to $1.18. The company's market cap stands at $8.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.